Surface markers of liver cancer stem cells and innovative targeted-therapy strategies for HCC.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Oncology Letters

• Publication date

  2017-12-08

• Fields of study

  Medicine

• Identifiers
  DOI 10.3892/ol.2017.7568PMID 29434903PMCID PMC5776936
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• CD133+ liver cancer stem cells resist interferon-gamma-induced autophagy

  2016cited by this paper
• Lysine-specific demethylase 1 promotes the stemness and chemoresistance of Lgr5+ liver cancer initiating cells by suppressing negative regulators of β-catenin signaling

  2015cited by this paper
• EpCAM-Antibody-Labeled Noncytotoxic Polymer Vesicles for Cancer Stem Cells-Targeted Delivery of Anticancer Drug and siRNA.

  2015cited by this paper
• Single-cell analysis reveals a stem-cell program in human metastatic breast cancer cells

  2015cited by this paper
• Epithelial cell adhesion molecule aptamer conjugated PEG-PLGA nanopolymersomes for targeted delivery of doxorubicin to human breast adenocarcinoma cell line in vitro.

  2015cited by this paper
• Identification of a distinct population of CD133+CXCR4+ cancer stem cells in ovarian cancer

  2015cited by this paper
• Side population cells separated from A549 lung cancer cell line possess cancer stem cell-like properties and inhibition of autophagy potentiates the cytotoxic effect of cisplatin.

  2015cited by this paper
• Therapeutics targeting CD90-integrin-AMPK-CD133 signal axis in liver cancer

  2015cited by this paper
• Effective Eradication of Glioblastoma Stem Cells by Local Application of an AC133/CD133-Specific T-cell-Engaging Antibody and CD8 T Cells.

  2015cited by this paper
• A novel peptide-based recognition probe for the sensitive detection of CD44 on breast cancer stem cells.

  2015cited by this paper
• Isolation of Cancer Stem Cells from Three Human Glioblastoma Cell Lines: Characterization of Two Selected Clones

  2014cited by this paper
• Intracellular targeting of CD44+ cells with self-assembling, protein only nanoparticles.

  2014cited by this paper
• Blockade of CD47‐mediated cathepsin S/protease‐activated receptor 2 signaling provides a therapeutic target for hepatocellular carcinoma

  2014cited by this paper
• Expression of intercellular adhesion molecule 1 by hepatocellular carcinoma stem cells and circulating tumor cells.

  2013cited by this paper
• Targeting chronic lymphocytic leukemia cells with a humanized monoclonal antibody specific for CD44

  2013cited by this paper
• Efficacy of Using Cancer Stem Cell Markers in Isolating and Characterizing Liver Cancer Stem Cells

  2013cited by this paper
• Label-retaining liver cancer cells are relatively resistant to sorafenib

  2013cited by this paper
• Targeting cancer stem cells with an 131I-labeled anti-AC133 monoclonal antibody in human colorectal cancer xenografts.

  2013cited by this paper
• Discrete nature of EpCAM+ and CD90+ cancer stem cells in human hepatocellular carcinoma

  2013cited by this paper
• Targeting CD133 in an in vivo ovarian cancer model reduces ovarian cancer progression.

  2013cited by this paper
• CD133-targeted paclitaxel delivery inhibits local tumor recurrence in a mouse model of breast cancer.

  2013cited by this paper
• CD44 and SSEA-4 positive cells in an oral cancer cell line HSC-4 possess cancer stem-like cell characteristics.

  2013cited by this paper
• The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors

  2012cited by this paper
• CD133+ liver cancer stem cells modulate radioresistance in human hepatocellular carcinoma.

  2012cited by this paper
• Screening of Peptides Bound to Breast Cancer Stem Cell Specific Surface Marker CD44 by Phage Display

  2012cited by this paper
• CD44s regulates the TGF-β-mediated mesenchymal phenotype and is associated with poor prognosis in patients with hepatocellular carcinoma.

  2012cited by this paper
• Expression and role of epithelial cell adhesion molecule in dysplastic nodule and hepatocellular carcinoma.

  2012cited by this paper
• Clinical implications of cancer stem cell biology in hepatocellular carcinoma.

  2012cited by this paper
• OV6⁺ tumor-initiating cells contribute to tumor progression and invasion in human hepatocellular carcinoma.

  2012cited by this paper
• A novel mouse CD133 binding-peptide screened by phage display inhibits cancer cell motility in vitro

  2012cited by this paper
• Cooperative effects of aminopeptidase N (CD13) expressed by nonmalignant and cancer cells within the tumor microenvironment

  2012cited by this paper
• Stem cells in liver diseases and cancer: Recent advances on the path to new therapies

  2012cited by this paper
• Overexpression of Thy1/CD90 in human hepatocellular carcinoma is associated with HBV infection and poor prognosis.

  2011cited by this paper
• The Power and the Promise of Liver Cancer Stem Cell Markers

  2011cited by this paper
• Management of hepatocellular carcinoma: An update

  2011cited by this paper
• Continuous Improvement of Survival Outcomes of Resection of Hepatocellular Carcinoma: A 20-Year Experience

  2011cited by this paper
• Cancer Stem Cells and Chemosensitivity

  2011cited by this paper
• EpCAM/CD3-Bispecific T-cell Engaging Antibody MT110 Eliminates Primary Human Pancreatic Cancer Stem Cells

  2011cited by this paper
• Highly osteogenic PDL stem cell clones specifically express elevated levels of ICAM1, ITGB1 and TERT

  2011cited by this paper
• microRNA-150 inhibits human CD133-positive liver cancer stem cells through negative regulation of the transcription factor c-Myb.

  2011cited by this paper
• Human hepatic stem cell and maturational liver lineage biology

  2011cited by this paper
• Prediction of Posthepatectomy Recurrence of Hepatocellular Carcinoma by Circulating Cancer Stem Cells: A Prospective Study

  2011cited by this paper
• CD13 is a therapeutic target in human liver cancer stem cells.

  2010cited by this paper
• Calreticulin Is the Dominant Pro-Phagocytic Signal on Multiple Human Cancers and Is Counterbalanced by CD47

  2010cited by this paper
• Time-Dependent Migration of Systemically Delivered Bone Marrow Mesenchymal Stem Cells to the Infarcted Heart

  2010cited by this paper
• EpCAM as a target in cancer therapy.

  2010cited by this paper
• Adecatumumab: an anti-EpCAM monoclonal antibody, from the bench to the bedside

  2010cited by this paper
• Characterization of the epithelial cell adhesion molecule (EpCAM)+ cell population in hepatocellular carcinoma cell lines

  2010cited by this paper
• Future perspectives in hepatocellular carcinoma.

  2010cited by this paper
• Expression of CD133 confers malignant potential by regulating metalloproteinases in human hepatocellular carcinoma.

  2010cited by this paper
• A2B5 Cells from Human Glioblastoma have Cancer Stem Cell Properties

  2010cited by this paper
• miR-130b Promotes CD133(+) liver tumor-initiating cell growth and self-renewal via tumor protein 53-induced nuclear protein 1.

  2010cited by this paper
• Hepatic stem cells and liver development.

  2010cited by this paper
• EpCAM, a new marker for cancer stem cells in hepatocellular carcinoma.

  2010cited by this paper
• Cancer stem/progenitor cells are highly enriched in CD133+CD44+ population in hepatocellular carcinoma

  2009cited by this paper
• Effect of CD133/prominin-1 antisense oligodeoxynucleotide on in vitro growth characteristics of Huh-7 human hepatocarcinoma cells and U251 human glioma cells.

  2009cited by this paper
• Cancer stem cell-directed therapies: recent data from the laboratory and clinic.

  2009cited by this paper
• CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells.

  2009cited by this paper
• CD133-positive hepatocellular carcinoma in an area endemic for hepatitis B virus infection

  2009cited by this paper
• Human CD34+/CD90+ ASCs Are Capable of Growing as Sphere Clusters, Producing High Levels of VEGF and Forming Capillaries

  2009cited by this paper
• EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features.

  2009cited by this paper
• Consensus report of the national cancer institute clinical trials planning meeting on pancreas cancer treatment.

  2009cited by this paper
• Expansion of CD133‐Expressing Liver Cancer Stem Cells in Liver‐Specific Phosphatase and Tensin Homolog Deleted on Chromosome 10‐Deleted Mice

  2009cited by this paper
• Cancer stem cells and hepatocellular carcinoma

  2009cited by this paper
• Cancer stem cell marker expression in hepatocellular carcinoma and liver metastases is not sufficient as single prognostic parameter.

  2009cited by this paper
• The emerging role of EpCAM in cancer and stem cell signaling.

  2009cited by this paper
• EpCAM expression in normal, non-pathological tissues.

  2008cited by this paper
• Aldehyde Dehydrogenase Discriminates the CD133 Liver Cancer Stem Cell Populations

  2008cited by this paper
• CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway

  2008cited by this paper
• Significance of CD90+ cancer stem cells in human liver cancer.

  2008cited by this paper
• EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma.

  2008cited by this paper
• CD133/prominin-1 is a potential therapeutic target for antibody-drug conjugates in hepatocellular and gastric cancers

  2008cited by this paper
• Identification of local and circulating cancer stem cells in human liver cancer

  2008cited by this paper
• Wnt/beta-catenin signaling contributes to activation of normal and tumorigenic liver progenitor cells.

  2008cited by this paper
• Expression and clinical significance of the stem cell marker CD133 in hepatocellular carcinoma

  2008cited by this paper
• Molecular Trafficking Mechanisms of Multipotent Mesenchymal Stem Cells Derived from Human Bone Marrow and Placenta

  2008cited by this paper
• Analysis of ABCG2 expression and side population identifies intrinsic drug efflux in the HCC cell line MHCC-97L and its modulation by Akt signaling.

  2008cited by this paper
• Identification and expansion of human colon-cancer-initiating cells

  2007cited by this paper
• CD133 positive hepatocellular carcinoma cells possess high capacity for tumorigenicity

  2007cited by this paper
• Identification and characterization of tumorigenic liver cancer stem/progenitor cells.

  2007cited by this paper
• Side population purified from hepatocellular carcinoma cells harbors cancer stem cell–like properties

  2006cited by this paper
• Characterization of CD133+ hepatocellular carcinoma cells as cancer stem/progenitor cells.

  2006cited by this paper
• Cancer stem cells.

  2006cited by this paper
• Liver stem cells and prospects for liver reconstitution by transplanted cells

  2006cited by this paper
• The clinicopathological and prognostic relevance of cytokeratin 7 and 19 expression in hepatocellular carcinoma. A possible progenitor cell origin

  2006cited by this paper
• Cancer stem cells--perspectives on current status and future directions: AACR Workshop on cancer stem cells.

  2006cited by this paper
• Characterization of a Side Population of Cancer Cells from Human Gastrointestinal System

  2006cited by this paper
• The SIRP family of receptors and immune regulation

  2006cited by this paper
• Highly efficacious nontoxic preclinical treatment for advanced metastatic breast cancer using combination oral UFT-cyclophosphamide metronomic chemotherapy.

  2006cited by this paper
• A tumorigenic subpopulation with stem cell properties in melanomas.

  2005cited by this paper
• Characteristics of rat bone marrow cells differentiated into a liver cell lineage and dynamics of the transplanted cells in the injured liver

  2005cited by this paper
• Negative Regulation of Phagocytosis in Macrophages by the CD47-SHPS-1 System1

  2005cited by this paper
• Alternative promoters regulate transcription of the gene that encodes stem cell surface protein AC133.

  2004cited by this paper
• Isolation of hepatoblasts based on the expression of Dlk/Pref-1

  2003cited by this paper
• The origin and liver repopulating capacity of murine oval cells

  2003cited by this paper
• Identification of a cancer stem cell in human brain tumors.

  2003cited by this paper
• in vivo Cell Lineage Analysis During Chemical Hepatocarcinogenesis in Rats Using Retroviral-Mediated Gene Transfer: Evidence for Dedifferentiation of Mature Hepatocytes

  2002cited by this paper
• Demonstration of direct lineage between hepatocytes and hepatocellular carcinoma in diethylnitrosamine‐treated rats

  2002cited by this paper
• Generation and characterization of p53 null transformed hepatic progenitor cells: oval cells give rise to hepatocellular carcinoma.

  2002cited by this paper
• Hepatic Progenitor Cells in Hepatocellular Adenomas

  2001cited by this paper

• Circulating Tumor Cells as Diagnostic and Therapeutic Biomarkers in Hepatocellular Carcinoma: Advancing Precision Oncology Through Liquid Biopsy

  2026cites this paper
• Advancements in cancer stem cell therapy: The effective integration of traditional Chinese medicine and nanotechnology.

  2026cites this paper
• Stemness CD24 activation promotes hepatocellular carcinoma progression via an immune escape mechanism

  2026cites this paper
• Liver cancer stem cells as novel diagnostic biomarkers.

  2025cites this paper
• Evaluation of hepatic cancer stem cells (CD73+, CD44+, and CD90+) induced by diethylnitrosamine in male rats and treatment with biologically synthesized silver nanoparticles

  2025cites this paper
• Implicating the cholecystokinin B receptor in liver stem cell oncogenesis

  2024cites this paper
• Application of hydrogels for targeting cancer stem cells in cancer treatment.

  2024cites this paper
• Cancer stem cells: an insight into the development of metastatic tumors and therapy resistance

  2023cites this paper
• Roles of cancer stem cells in cancer immune surveillance

  2023cites this paper
• Assessment of hyaluronic acid-modified imatinib mesylate cubosomes through CD44 targeted drug delivery in NDEA-induced hepatic carcinoma.

  2022cites this paper
• Stem Cells as A Double-Edged Sword in Treatment of Liver Diseases

  2022cites this paper
• Therapeutic targeting of hepatocellular carcinoma cells with antrocinol, a novel, dual-specificity, small-molecule inhibitor of the KRAS and ERK oncogenic signaling pathways.

  2022cites this paper
• Extracellular Vesicles and Resistance to Anticancer Drugs: A Tumor Skeleton Key for Unhinging Chemotherapies

  2022cites this paper
• Matrix Stiffness Potentiates Stemness of Liver Cancer Stem Cells Possibly via the Yes-Associated Protein Signal.

  2022cites this paper
• The Human TOR Signaling Regulator Is the Key Indicator of Liver Cancer Patients’ Overall Survival: TIPRL/LC3/CD133/CD44 as Potential Biomarkers for Early Liver Cancers

  2021cites this paper
• The Role of IGF/IGF-1R Signaling in Hepatocellular Carcinomas: Stemness-Related Properties and Drug Resistance

  2021cites this paper
• Pluripotency inducing Yamanaka factors: role in stemness and chemoresistance of liver cancer

  2021cites this paper
• Interplay of autophagy and cancer stem cells in hepatocellular carcinoma

  2021cites this paper
• Chronic alcohol exposure promotes HCC stemness and metastasis through β-catenin/miR-22-3p/TET2 axis

  2021influential citation
• Toward radiotheranostics in cancer stem cells: a promising initial step for tumour eradication

  2021cites this paper
• Hepatitis C virus infects and perturbs liver stem cells

  2021cites this paper
• МОЛЕКУЛЯРНЫЕ МАРКЕРЫ ПОВЕРХНОСТНЫХ МЕМБРАН ДЛЯ ИДЕНТИФИКАЦИИ ПОПУЛЯЦИЙ СТВОЛОВЫХ КЛЕТОК ОПУХОЛЕЙ (СИСТЕМАТИЧЕСКИЙ ОБЗОР)

  2020cites this paper
• Cancer Stem Cells as Therapeutic Targets for Gastrointestinal Cancers

  2020cites this paper
• IMMUNOHISTOCHEMICAL EXPRESSION OF CD44 IN PATIENTS WITH HEPATOCELLULAR CARCINOMA

  2020influential citation
• Tonicity-responsive enhancer-binding protein promotes stemness of liver cancer and cisplatin resistance

  2020cites this paper
• Cancer cells stemness: A doorstep to targeted therapy.

  2020cites this paper
• Dysregulated microRNAs in Hepatitis B Virus-Related Hepatocellular Carcinoma: Potential as Biomarkers and Therapeutic Targets

  2020cites this paper
• Potential targets and molecular mechanism of miR-331-3p in hepatocellular carcinoma identified by weighted gene coexpression network analysis

  2020cites this paper
• 4-Acetylantroquinonol B from antrodia cinnamomea enhances immune function of dendritic cells against liver cancer stem cells.

  2019cites this paper
• Role of TGF-β1 and C-Kit Mutations in the Development of Hepatocellular Carcinoma in Hepatitis C Virus-Infected Patients: in vitro Study

  2019cites this paper
• Roles of mitochondria in liver cancer stem cells.

  2019cites this paper
• Signal transducer and activator of transcription 3 promotes the Warburg effect possibly by inducing pyruvate kinase M2 phosphorylation in liver precancerous lesions

  2019cites this paper
• Immunologic Targeting of Cancer Stem Cells.

  2019cites this paper
• miR-532-3p promotes hepatocellular carcinoma progression by targeting PTPRT.

  2019cites this paper
• Stemness features in liver cancer

  2018cites this paper
• Therapeutic Opportunities of Targeting Histone Deacetylase Isoforms to Eradicate Cancer Stem Cells

  2018cites this paper
• miRNA122a regulation of gene therapy vectors targeting hepatocellular cancer stem cells

  2018influential citation
• Aspirin enhances the sensitivity of hepatocellular carcinoma side population cells to doxorubicin via miR-491/ABCG2

  2018cites this paper
• Epithelial to mesenchymal transition is involved in ethanol promoted hepatocellular carcinoma cells metastasis and stemness

  2018influential citation
• 4Mu Decreases CD47 Expression on Hepatic Cancer Stem Cells and Primes a Potent Antitumor T Cell Response Induced by Interleukin-12.

  2018cites this paper
• Associations between CD133, CK19 and G2/M in cirrhotic HCV (genotype-4) patients with or without accompanying tumor

  2018influential citation